english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Metformin during pregnancy: possible risk of malformations

 Adverse Effects  Metformin does not appear to be associated with a high risk of malformations, but the available data do not rule out the possibility that metformin exposure increases the risk of certain rare but serious malformations.
Full article (3 pages) available for download by subscribers
1 February 2023

Drugs to avoid in the name of better patient care: 2023 update

Drugs to avoid  DRUGS TO AVOID - 2023 UPDATE  To make it easier to choose quality care, and to prevent disproportionate harm to patients, Prescrire has published its annual update of drugs to avoid. Learn more...
Full article (11 pages) available for free download
1 February 2023

Universities challenge the impact factor

At the start of the 2020s, steps are being taken in some countries to improve the assessment of research.
1 February 2023

Revolving door between the public and private sectors: conflict of interest

 Editorial  In Europe, as in the United States, senior public officials sometimes go on to occupy positions in the private, for-profit sector, and vice versa. The blurring of roles and conflicts of interest this situation engenders are detrimental to the public interest. There are many such examples in the health sector.
1 January 2023

Relugolix + estradiol + norethisterone (Ryeqo°) in uterine fibroids: not acceptable

  Marketing Authorisations  The three-drug combination of relugolix + estradiol + norethisterone was mainly evaluated in two placebo-controlled trials. It markedly reduced menstrual bleeding in most women, but not fibroid volume, and no conclusive evidence of effects on other symptoms was obtained.
Full article (4 pages) available for download by subscribers
1 January 2023

Setmelanotide (Imcivree°) in certain, very rare, genetic forms of obesity: possibly helpful

  Marketing Authorisations  Evaluation of setmelanotide in the very rare patients with obesity due to POMC, PCSK1 or LEPR mutations is only based on two non-comparative trials, in a total of 30 patients treated for one year. These trials suggest that daily subcutaneous injections of setmelanotide help patients feel less hungry, and consequently lose weight, especially those with POMC deficiency.
Full article (3 pages) available for download by subscribers
1 January 2023

Trimebutine: too many cardiac risks

 Adverse Effects  In 2021, using data from 444 575 patients, a Korean team observed that the risk of QT interval prolongation linked to hydroxychloroquine was greater in patients who were also exposed to trimebutine.
Full article available for download by subscribers
1 January 2023

Impending changes to European pharmaceutical regulations: part II

 ADVANCING HEALTHCARE POLICY  In order to prepare its new "Pharmaceutical Strategy for Europe", the European Commission organised several public consultations in advance. The present article reproduces extensive excerpts from a report published by the European Parliamentary Research Service, produced in connection with these consultations, which calls for the creation of a "European Medicines Infrastructure".
Full article (3 pages) available for free download
1 January 2023

Dapivirine vaginal ring in the prevention of HIV

 Marketing Authorisations  Fragile data from a single clinical trial suggest that the dapivirine vaginal ring has at best partial efficacy in the prevention of HIV infection, with a considerable margin of uncertainty.
Full article (4 pages) available for download by subscribers.
1 December 2022

Europe and medicines

 Editorial  The European Commission is due to propose changes to European pharmaceutical legislation in early 2023, in what has been presented as a major revision. No doubt the industry's lobby groups will attempt to shape the legislation in their favour. But civil society organisations will also have their say.
1 December 2022

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90